MRI T1w and T2w Combined Features for Detecting NeurodegenerationID# 2018-4728
A novel method is disclosed for early Parkinson’s disease (PD) detection. A simple MRI contrast, the T1w/T2w ratio, can serve as an in vivo marker for PD, showing early PD-related changes in the substantia nigra (SN).
Application & Market Utility
This technology is used in the diagnosis, differential diagnosis, and progession monitoring of Parkinson’s disease. Because of its simple implementation, high resolution, and wide availability, this novel method has high translational value for clinincal practice and research. In addition, the T1w/T2w ratio may also be able to guage disease severity as well.
Complete further studies including PD patients with different durations and stages. Complete a longitudinal follow-up. Patent pending. Seeking licensing opportunities.